Targeted therapy for drug-tolerant persister cells after imatinib treatment for gastrointestinal stromal tumours.

Tomo IshidaTsuyoshi TakahashiYukinori KurokawaToshirou NishidaSeiichi HirotaSatoshi SeradaMinoru FujimotoTetsuji NakaRyugo TeranishiTakuro SaitoKotaro YamashitaKoji TanakaKazuyoshi YamamotoTomoki MakinoMakoto YamasakiKiyokazu NakajimaHidetoshi EguchiYuichiro Doki

Published in: British journal of cancer (2021)

RSL3 combined with TKI may be a promising therapy for both GIST and epidermal growth factor receptor-mutated lung cancer.

Keyphrases

epidermal growth factor receptor
tyrosine kinase
advanced non small cell lung cancer
induced apoptosis
cell cycle arrest
cell proliferation
combination therapy
oxidative stress
wild type
electronic health record